Medtronic PLC $MDT Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in Medtronic PLC (NYSE:MDT) by 93.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 627,689 shares of the medical technology company’s stock after selling 9,106,059 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Medtronic were worth $49,104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the business. Brighton Jones LLC grew its stake in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after acquiring an additional 381 shares during the last quarter. Jump Financial LLC purchased a new position in Medtronic in the second quarter valued at approximately $299,000. Main Street Financial Solutions LLC raised its stake in Medtronic by 28.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after acquiring an additional 3,218 shares in the last quarter. Finally, HUB Investment Partners LLC increased its position in shares of Medtronic by 21.3% during the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after purchasing an additional 3,376 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MDT shares. Jefferies Financial Group reaffirmed a “hold” rating and issued a $88.00 target price on shares of Medtronic in a report on Thursday, June 4th. Bank of America increased their target price on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday. Rothschild & Co Redburn cut their price target on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Mizuho set a $115.00 price objective on Medtronic in a report on Wednesday. Finally, Robert W. Baird lifted their target price on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.96.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Broad earnings beat and stronger outlook: Medtronic reported adjusted EPS of $1.45, above the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates of $9.55 billion. Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Medtronic fiscal 2027 results
• Positive Sentiment: Growth was broad-based: Cardiovascular revenue rose 19.5%, neuroscience increased 10.3%, medical surgical grew 10.0% and diabetes advanced 16.9%. Analysts characterized the results as evidence of a potential growth acceleration across both established franchises and newer platforms. Medtronic beat-and-raise analysis
• Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining distribution rights for its Sentire surgical system in select markets outside the United States. It also agreed to invest up to $80 million in Pi-Cardia to support complex TAVR procedures. These moves could broaden Medtronic’s long-term growth opportunities in minimally invasive surgery and structural heart care. Cornerstone Robotics partnership
• Positive Sentiment: Analyst support increased: RBC reaffirmed an Outperform rating and set a $118 price target. BTIG raised its target to $100 and maintained a Buy rating, while Baird lifted its target to $100. These revisions indicate improving confidence in Medtronic’s earnings trajectory. Analyst price-target revisions
• Neutral Sentiment: Some caution remains: Stifel raised its price target to $95 but kept a Hold rating, and Baird retained a Neutral rating despite its higher target. The second-quarter EPS outlook of $1.32-$1.34 is below the $1.35 consensus, suggesting investors may continue to watch execution and the sustainability of the recent growth acceleration.

Medtronic Trading Up 0.1%

Shares of MDT stock opened at $92.10 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm has a market cap of $117.89 billion, a P/E ratio of 22.69, a PEG ratio of 2.15 and a beta of 0.56. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The firm’s 50-day simple moving average is $86.27 and its 200-day simple moving average is $85.35.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same period in the previous year, the company earned $1.26 EPS. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.96 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s payout ratio is 70.94%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).